Risco cardiovascular em pessoas com colangite biliar primária, revisão da literatura
Resumo
A colangite biliar primária (CBP ) é uma doença autoimune multifatorial (fatores genéticos, desencadeadores ambientais como localização geográfica, tabagismo, microrganismos, xenobióticos).
O objetivo deste estudo é descrever os fatores de risco relacionados à colangite biliar primária e como ela incide no risco cardiovascular. Foi realizada uma busca bibliográfica em bases de dados de pesquisas originais, estudos de coorte prospectivos e retrospectivos, estudos de casos e controles, revisões sistemáticas e metanálises, nos quais foram utilizadas palavras-chave relacionadas.
Encontrou-se uma relação entre as alterações na CBP e o perfil lipídico, que aumentava o estresse oxidativo e a disfunção endotelial; no entanto, os estudos que tentam determinar o efeito da hipercolesterolemia sobre o aumento do risco cardiovascular (RCV ) em pacientes com CBP têm sido contraditórios. A esteatose hepática está relacionada com o aumento das doenças cardiovasculares (ECV ) e é comum em doenças hepáticas crônicas como hepatite B e C crônicas e a doença hepática gordurosa não alcoólica. A CBP pode ter manifestações extra-hepáticas, dentre as quais as mais prevalentes são as pulmonares, como a doença pulmonar intersticial e a hipertensão pulmonar. Este artigo apresenta a relação entre a CBP e seus principais fatores de risco e o desenvolvimento de doenças tanto hepáticas quanto extra-hepáticas que aumentam o risco cardiovascular.
Downloads
Referências
Suraweera D, Fanous C, Jimenez M, Tong MJ, Saab S. Risk of cardiovascular events in patients with primary biliary cholangitis-systematic review. J Clin Transl Hepatol. 2018;6(2):119–26.
Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol [Internet]. 2020;17(2):93–110. Available from: http://dx.doi.org/10.1038/s41575-019-0226-7
Reshetnyak VI, Maev I V. Features of Lipid Metabolism Disorders in Primary Biliary Cholangitis. Biomedicines. [Internet]. 2022;10(12). Disponible en: https://doi.org/10.3390%2Fbiomedicines10123046
Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis [Internet]. 2014;232(1):99–109. Available from: http://dx.doi.org/10.1016/j.atherosclerosis.2013.10.030
Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis. 2007;194(2):293–9. Disponible en: https://doi.org/10.1016/j.atherosclerosis.2006.11.036
Yao S, Iwashita A, Yagi S, Watanabe H, Nishio T, Koyama Y, et al. Acute coronary syndrome after liver transplantation in a young primary biliary cholangitis recipient with dyslipidemia: a case report. Surg Case Reports [Internet]. 2022;8(1):1–7. Available from: https://doi.org/10.1186/s40792-022-01470-1
Park B, Islam S, Vemulapalli RC, Shreve ME. Primary biliary cholangitis presenting as acute ischemic stroke: A rare association. Clin Case Reports. [Internet]. 2020;8(2):274–7. Disponible en: https://doi.org/10.1002%2Fccr3.2590
Floreani A, Cazzagon N, Franceschet I, Canesso F, Salmaso L and Baldo V. Metabolic Syndrome Associated With Primary Biliary Cirrhosis. J Clin Gastroenterol. [Internet]. 2015;49(1):57–60.Disponible en: https://doi.org/10.1097/mcg.0000000000000029
Cazzagon N, Dal Lin C, Famoso G, Montisci R, Franceschet I, Floreani A, et al. Coronary flow reserve in patients with primary biliary cholangitis. Dig Liver Dis [Internet]. 2019;51(4):542–8. Disponible en:https://doi.org/10.1016/j.dld.2018.10.016
Bian S, Chen H, Wang L, Fei Y, Yang Y, Peng L, et al. Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal surveybased study. PLoS One. [Internet]. 2018;13(3):1–9. Disponible en: https://doi.org/10.1371/journal.pone.0194397
Maeda MH, Tsuji S, Shimizu J. Inflammator myopathies associated with anti-mitochondrial antibodies. Brain. [Internet]. 2012;135(6):1767–77. Disponible en: https://doi.org/10.1093/brain/aws106
Kenneth R. Feingold M. Endotext [Internet]. Feingold KR, Anawalt B, Blackman MR, et al. E, editor. South Dartmouth (MA): MDText.com, Inc.; 2000-.; 2021. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK305896/
Chen L, Chen XW, Huang X, Song BL, Wang Y, Wang Y. Regulation of glucose and lipid metabolism in health and disease. Sci China Life Sci. [Internet].62(11):1420–58. Disponible en: https://doi.org/10.1007/s11427-019-1563-3
Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, et al.Pathophysiology of Atherosclerosis. Int J Mol Sci.[Internet]. 2022;23(6):1–38. Disponible en: https://doi.org/10.3390%2Fijms23063346
Sanuja Fernando, Bursill C, Nicholls S and Psaltis P. Pathophysiology of Atherosclerosis. Third Edit. Fitridge R, editor. Springer; 2020. 19–46 p. Disponible en: http://dx.doi.org/10.1007/978-3-030-43683-4_2
Loaeza-del Castillo AM, Gaytán-Santillán A, López-Tello A, Merit MVA, Milke-García M del P,Flores-Rodríguez J, et al. Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis. Ann Hepatol [Internet]. 2019;18(6):879–82. Disponible en:https://doi.org/10.1016/j.aohep.2019.07.006
Wah-Suarez MI, Danford CJ, Patwardhan VR, Jiang ZG, Bonder A. Hyperlipidaemia in primary biliary cholangitis: Treatment, safety and efficacy. Frontline Gastroenterol. [Internet] 2019;10(4):401–8. Disponible en: https://doi.org/10.1136/flgastro-2018-101124
Zhang Y, Hu X, Chang J, Chen J, Han X, Zhang T, et al. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol [Internet]. 2021;21(1):1–8. Disponible en: https://doi.org/10.1186/s12876-021-01974-4
Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut. [Internet]. 2006;55(12):1795–800. Disponible en: https://doi.org/10.1136%2Fgut.2005.079814
Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. [Internet]. 2002;51(2):265–9. Disponible en: https://doi.org/10.1136/gut.51.2.265
Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: What is the risk? Hepatology. [Internet]. 1992;15(5):858–62.Disponible en: https://doi.org/10.1002/hep.1840150518
Van Dam GM, Gips CH. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol. [Internet]. 1997;32(1):77–83. Disponible en: https://doi.org/10.3109/00365529709025067
Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: A populationbased cohort study. Am J Gastroenterol. [Internet]. 2008;103(11):2784–8. Disponible en: https://doi.org/10.1111/j.1572-0241.2008.02092.x
Doycheva I, Chen C, Pan JJ, Levy C. Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease. World J Hepatol. [Internet]. 2011;3(4):93–8. Disponible en: https://doi.org/10.4254%2Fwjh.v3.i4.93
Zöller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: A nationwide follow-up study from Sweden. PLoS One. [Internet]. 2012;7(3):1–8. Disponible en: https://doi.org/10.1371/journal.pone.0033442
Wang C, Zhao P, Liu W. Brief Communication Risk of incident coronary artery disease in patients with primary biliary cirrhosis. Int J Clin Exp Med [Internet]. 2014;7(9):2921–4. Available from: www.ijcem.com
Gîrleanu I, Trifan A, Huiban L, Muzîca C, Petrea OC, Sîngeap AM, et al. Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury. Life. [Internet]. 2022;12(7). Disponible en: https://doi.org/10.3390%2Flife12071036
Cardinale V, Lleo A. Coronary flow reserve is an innovative tool for the early detection of cardiovascular dysfunction in primary biliary cholangitis patients. Dig Liver Dis [Internet]. 2019;51(4):549–50. Available from: https://doi.org/10.1016/j.dld.2018.11.017
Jones DEJ, Hollingsworth K, Fattakhova G, MacGowan G, Taylor R, Blamire A, et al. Impaired cardiovascular function in primary biliary cirrhosis. Am J Physiol - Gastrointest Liver Physiol. [Internet]. 2010;298(5):764–73. Disponible en: https://doi.org/10.1152%2Fajpgi.00501.2009
Copyright (c) 2024 Revista Med
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
